questionsmedicales.fr
Enzymes et coenzymes
Enzymes
Transferases
Glycosyltransferase
Pentosyltransferases
ADP ribose transferases
ADP ribose transferases : Questions médicales fréquentes
Termes MeSH sélectionnés :
Randomized Controlled Trials as Topic
Diagnostic
5
Marqueurs biologiques
ADP-ribose
Tests enzymatiques
Enzymes
Réparation de l'ADN
Troubles métaboliques
Imagerie médicale
Enzymes
Symptômes
5
Maladies neurodégénératives
Cancer
Troubles cognitifs
Mémoire
Enzymes
Variabilité des symptômes
Anomalies cutanées
Troubles métaboliques
Asymptomatique
Dysfonction enzymatique
Prévention
5
Prévention
Mode de vie sain
Exercice physique
Santé cellulaire
Traitements
5
Thérapie génique
Médicaments ciblés
Essais cliniques
Inhibiteurs
Médecine personnalisée
Dysfonctionnement enzymatique
Gestion des symptômes
Traitements
Complications
5
Cancers
Maladies auto-immunes
Maladies cardiovasculaires
Dysfonctionnement enzymatique
Qualité de vie
Complications
Antécédents médicaux
Prévisibilité
Facteurs de risque
5
Facteurs génétiques
Toxines
Vieillissement
Facteurs de risque
Antécédents familiaux
Risque
Alimentation
Antioxydants
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "ADP ribose transferases : Questions médicales les plus fréquentes",
"headline": "ADP ribose transferases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les ADP ribose transferases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-30",
"dateModified": "2025-04-24",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "ADP ribose transferases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Pentosyltransferases",
"url": "https://questionsmedicales.fr/mesh/D010430",
"about": {
"@type": "MedicalCondition",
"name": "Pentosyltransferases",
"code": {
"@type": "MedicalCode",
"code": "D010430",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.400.725"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "NAD nucleosidase",
"alternateName": "NAD+ Nucleosidase",
"url": "https://questionsmedicales.fr/mesh/D009244",
"about": {
"@type": "MedicalCondition",
"name": "NAD nucleosidase",
"code": {
"@type": "MedicalCode",
"code": "D009244",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.400.725.115.660"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "ADP-ribosyl cyclase",
"alternateName": "ADP-ribosyl Cyclase",
"url": "https://questionsmedicales.fr/mesh/D036541",
"about": {
"@type": "MedicalCondition",
"name": "ADP-ribosyl cyclase",
"code": {
"@type": "MedicalCode",
"code": "D036541",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.400.725.115.660.060"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Poly(ADP-ribose) polymerases",
"alternateName": "Poly(ADP-ribose) Polymerases",
"url": "https://questionsmedicales.fr/mesh/D011065",
"about": {
"@type": "MedicalCondition",
"name": "Poly(ADP-ribose) polymerases",
"code": {
"@type": "MedicalCode",
"code": "D011065",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.400.725.115.690"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Poly (ADP-Ribose) polymerase-1",
"alternateName": "Poly (ADP-Ribose) Polymerase-1",
"url": "https://questionsmedicales.fr/mesh/D000071137",
"about": {
"@type": "MedicalCondition",
"name": "Poly (ADP-Ribose) polymerase-1",
"code": {
"@type": "MedicalCode",
"code": "D000071137",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.400.725.115.690.420"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Tankyrases",
"alternateName": "Tankyrases",
"url": "https://questionsmedicales.fr/mesh/D038501",
"about": {
"@type": "MedicalCondition",
"name": "Tankyrases",
"code": {
"@type": "MedicalCode",
"code": "D038501",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.400.725.115.690.840"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "ADP ribose transferases",
"alternateName": "ADP Ribose Transferases",
"code": {
"@type": "MedicalCode",
"code": "D036002",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Anthony K L Leung",
"url": "https://questionsmedicales.fr/author/Anthony%20K%20L%20Leung",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA."
}
},
{
"@type": "Person",
"name": "Morgan Dasovich",
"url": "https://questionsmedicales.fr/author/Morgan%20Dasovich",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA."
}
},
{
"@type": "Person",
"name": "Mohsen Badiee",
"url": "https://questionsmedicales.fr/author/Mohsen%20Badiee",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205."
}
},
{
"@type": "Person",
"name": "Yong Zhang",
"url": "https://questionsmedicales.fr/author/Yong%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, California 90089, United States."
}
},
{
"@type": "Person",
"name": "Sua Myong",
"url": "https://questionsmedicales.fr/author/Sua%20Myong",
"affiliation": {
"@type": "Organization",
"name": "Program in Cell, Molecular, Developmental Biology, and Biophysics, Johns Hopkins University, Baltimore, Maryland 21218, United States."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Topical diquafosol versus hyaluronic acid for the treatment of dry eye disease: a meta-analysis of randomized controlled trials.",
"datePublished": "2023-05-10",
"url": "https://questionsmedicales.fr/article/37162564",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00417-023-06083-4"
}
},
{
"@type": "ScholarlyArticle",
"name": "The UPDATE trial (UVB Phototherapy in Dermatology for ATopic Eczema): study protocol for a randomized controlled trial of narrowband UVB with optimal topical therapy versus optimal topical therapy in patients with atopic eczema.",
"datePublished": "2024-07-16",
"url": "https://questionsmedicales.fr/article/39014498",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13063-024-08334-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Design and Methodological Issues of Within-Person (Split-Body) Randomized Controlled Trials Evaluating a Topical Treatment: A Systematic Review.",
"datePublished": "2023-03-29",
"url": "https://questionsmedicales.fr/article/36990057",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1159/000530149"
}
},
{
"@type": "ScholarlyArticle",
"name": "Laser and light therapy combined with topical minoxidil for alopecia areata: a systematic review and meta-analysis of randomized controlled trials.",
"datePublished": "2023-02-17",
"url": "https://questionsmedicales.fr/article/36800063",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10103-023-03734-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "Nd:YAG/Er:YAG dual laser vs. topical steroid to treat vulvar lichen sclerosus: study protocol of a randomized controlled trial.",
"datePublished": "2023-05-05",
"url": "https://questionsmedicales.fr/article/37145134",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00404-023-07055-z"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Transferases",
"item": "https://questionsmedicales.fr/mesh/D014166"
},
{
"@type": "ListItem",
"position": 5,
"name": "Glycosyltransferase",
"item": "https://questionsmedicales.fr/mesh/D016695"
},
{
"@type": "ListItem",
"position": 6,
"name": "Pentosyltransferases",
"item": "https://questionsmedicales.fr/mesh/D010430"
},
{
"@type": "ListItem",
"position": 7,
"name": "ADP ribose transferases",
"item": "https://questionsmedicales.fr/mesh/D036002"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : ADP ribose transferases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur ADP ribose transferases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-08",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur ADP ribose transferases",
"description": "Comment diagnostiquer une dysfonction des ADP ribose transferases ?\nQuels marqueurs biochimiques sont associés aux ADP ribose transferases ?\nY a-t-il des tests spécifiques pour les ADP ribose transferases ?\nQuels symptômes peuvent indiquer un problème avec ces enzymes ?\nLes tests d'imagerie sont-ils utiles pour ces enzymes ?",
"url": "https://questionsmedicales.fr/mesh/D036002?mesh_terms=Randomized+Controlled+Trials+as+Topic#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur ADP ribose transferases",
"description": "Quels symptômes sont liés à une déficience en ADP ribose transferases ?\nPeut-on observer des symptômes neurologiques ?\nLes symptômes varient-ils selon le type d'enzyme ?\nY a-t-il des symptômes cutanés associés ?\nLes symptômes sont-ils toujours présents ?",
"url": "https://questionsmedicales.fr/mesh/D036002?mesh_terms=Randomized+Controlled+Trials+as+Topic#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur ADP ribose transferases",
"description": "Peut-on prévenir les dysfonctionnements des ADP ribose transferases ?\nY a-t-il des facteurs environnementaux à éviter ?\nLes dépistages réguliers sont-ils recommandés ?\nL'exercice physique aide-t-il à prévenir ces dysfonctionnements ?\nLes vaccinations ont-elles un rôle préventif ?",
"url": "https://questionsmedicales.fr/mesh/D036002?mesh_terms=Randomized+Controlled+Trials+as+Topic#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur ADP ribose transferases",
"description": "Quels traitements existent pour les dysfonctionnements enzymatiques ?\nLes suppléments peuvent-ils aider ?\nY a-t-il des traitements expérimentaux ?\nLes traitements sont-ils personnalisés ?\nLes traitements sont-ils curatifs ?",
"url": "https://questionsmedicales.fr/mesh/D036002?mesh_terms=Randomized+Controlled+Trials+as+Topic#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur ADP ribose transferases",
"description": "Quelles complications peuvent survenir avec ces dysfonctionnements ?\nLes complications sont-elles réversibles ?\nY a-t-il un risque accru de maladies cardiovasculaires ?\nLes complications affectent-elles la qualité de vie ?\nLes complications sont-elles prévisibles ?",
"url": "https://questionsmedicales.fr/mesh/D036002?mesh_terms=Randomized+Controlled+Trials+as+Topic#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur ADP ribose transferases",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge est-il un facteur de risque ?\nLe stress a-t-il un impact sur ces enzymes ?\nLes antécédents familiaux influencent-ils le risque ?\nL'alimentation joue-t-elle un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D036002?mesh_terms=Randomized+Controlled+Trials+as+Topic#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction des ADP ribose transferases ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses biochimiques peuvent être utilisés pour évaluer leur activité."
}
},
{
"@type": "Question",
"name": "Quels marqueurs biochimiques sont associés aux ADP ribose transferases ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les niveaux d'ADP-ribose libre et de protéines modifiées peuvent servir de marqueurs."
}
},
{
"@type": "Question",
"name": "Y a-t-il des tests spécifiques pour les ADP ribose transferases ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques spécifiques peuvent mesurer l'activité des ADP ribose transferases."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec ces enzymes ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies dans la réparation de l'ADN ou des troubles métaboliques peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les tests d'imagerie sont-ils utiles pour ces enzymes ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les tests d'imagerie ne sont pas utilisés pour diagnostiquer les dysfonctionnements enzymatiques."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une déficience en ADP ribose transferases ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles de la réparation de l'ADN, des maladies neurodégénératives et des cancers."
}
},
{
"@type": "Question",
"name": "Peut-on observer des symptômes neurologiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles cognitifs et des problèmes de mémoire peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type d'enzyme ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, différents types d'ADP ribose transferases peuvent entraîner des symptômes variés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes cutanés associés ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies cutanées peuvent apparaître en raison de troubles métaboliques liés aux enzymes."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils toujours présents ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, certains patients peuvent être asymptomatiques malgré une dysfonction enzymatique."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les dysfonctionnements des ADP ribose transferases ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et un mode de vie sain peuvent réduire les risques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs environnementaux à éviter ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des toxines et à des radiations peut affecter l'activité enzymatique."
}
},
{
"@type": "Question",
"name": "Les dépistages réguliers sont-ils recommandés ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des dépistages peuvent être utiles pour les personnes à risque élevé de maladies associées."
}
},
{
"@type": "Question",
"name": "L'exercice physique aide-t-il à prévenir ces dysfonctionnements ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut améliorer la santé cellulaire et enzymatique."
}
},
{
"@type": "Question",
"name": "Les vaccinations ont-elles un rôle préventif ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les vaccinations ne sont pas directement liées à la prévention des dysfonctionnements enzymatiques."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour les dysfonctionnements enzymatiques ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies géniques et des médicaments ciblés peuvent être envisagés."
}
},
{
"@type": "Question",
"name": "Les suppléments peuvent-ils aider ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des suppléments d'ADP-ribose peuvent être envisagés, mais leur efficacité n'est pas prouvée."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des essais cliniques sur des inhibiteurs spécifiques des ADP ribose transferases sont en cours."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent être adaptés en fonction du type de dysfonctionnement enzymatique."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils curatifs ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, la plupart des traitements visent à gérer les symptômes plutôt qu'à guérir la condition."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec ces dysfonctionnements ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des cancers, des maladies auto-immunes et des troubles neurologiques peuvent se développer."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de maladies cardiovasculaires ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des études montrent un lien entre dysfonctionnement enzymatique et maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la qualité de vie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent significativement altérer la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles prévisibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être anticipées en fonction des antécédents médicaux."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs génétiques, l'exposition à des toxines et le mode de vie jouent un rôle."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le vieillissement peut affecter l'activité des ADP ribose transferases."
}
},
{
"@type": "Question",
"name": "Le stress a-t-il un impact sur ces enzymes ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress oxydatif peut altérer l'activité des ADP ribose transferases."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux influencent-ils le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies liées peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en antioxydants peut réduire le risque de dysfonctionnement enzymatique."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 24/04/2025
Contenu vérifié selon les dernières recommandations médicales
11 publications dans cette catégorie
Affiliations :
Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA.
McKusick-Nathans Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
5 publications dans cette catégorie
Affiliations :
Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA.
Department of Chemistry, Krieger School of Arts and Sciences, Johns Hopkins University, Baltimore, MD 21218, USA.
Publications dans "ADP ribose transferases" :
5 publications dans cette catégorie
Affiliations :
Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205.
Publications dans "ADP ribose transferases" :
4 publications dans cette catégorie
Affiliations :
Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, California 90089, United States.
Department of Chemistry, Dornsife College of Letters, Arts and Sciences, University of Southern California, Los Angeles, California 90089, United States.
Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California 90089, United States.
Research Center for Liver Diseases, University of Southern California, Los Angeles, California 90089, United States.
Publications dans "ADP ribose transferases" :
4 publications dans cette catégorie
Affiliations :
Program in Cell, Molecular, Developmental Biology, and Biophysics, Johns Hopkins University, Baltimore, Maryland 21218, United States.
Department of Biophysics, Johns Hopkins University, Baltimore, Maryland 21218, United States.
Physics Frontier Center (Center for the Physics of Living Cells), University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, United States.
Publications dans "ADP ribose transferases" :
3 publications dans cette catégorie
Affiliations :
Laboratory of Signaling and Gene Regulation, Cecil H. and Ida Green Center for Reproductive Biology Sciences, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Section of Laboratory Research, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Electronic address: Cristel.Camacho@utsouthwestern.edu.
Publications dans "ADP ribose transferases" :
3 publications dans cette catégorie
Affiliations :
Department of Neurology, Johns Hopkins University, School of Medicine, Baltimore, MD 21205, USA.
Publications dans "ADP ribose transferases" :
3 publications dans cette catégorie
Affiliations :
Department of Neurology, Johns Hopkins University, School of Medicine, Baltimore, MD 21205, USA.
Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University, School of Medicine, Baltimore, MD 21205, USA.
Department of Neuroscience, Johns Hopkins University, School of Medicine, Baltimore, MD 21205, USA.
Publications dans "ADP ribose transferases" :
3 publications dans cette catégorie
Affiliations :
Department of Neurology, Johns Hopkins University, School of Medicine, Baltimore, MD 21205, USA.
Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University, School of Medicine, Baltimore, MD 21205, USA.
Department of Neuroscience, Johns Hopkins University, School of Medicine, Baltimore, MD 21205, USA.
Publications dans "ADP ribose transferases" :
3 publications dans cette catégorie
Affiliations :
Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands. filippov@chem.leidenuniv.nl.
Publications dans "ADP ribose transferases" :
3 publications dans cette catégorie
Publications dans "ADP ribose transferases" :
2 publications dans cette catégorie
Affiliations :
UPMC Cancer Institute and Department of Pharmacology and Chemical Biology at the University of Pittsburgh, Hillman Cancer Center, 5115 Centre Avenue, Pittsburgh, PA, 15213, USA. elf115@pitt.edu.
Publications dans "ADP ribose transferases" :
2 publications dans cette catégorie
Affiliations :
Molecular Toxicology Group, University of Konstanz, Konstanz, Germany.
Publications dans "ADP ribose transferases" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Signaling and Gene Regulation, Cecil H. and Ida Green Center for Reproductive Biology Sciences, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Section of Laboratory Research, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Publications dans "ADP ribose transferases" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Signaling and Gene Regulation, Cecil H. and Ida Green Center for Reproductive Biology Sciences, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Section of Laboratory Research, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Electronic address: Lee.Kraus@utsouthwestern.edu.
Publications dans "ADP ribose transferases" :
2 publications dans cette catégorie
Affiliations :
Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, California 90089, United States.
Publications dans "ADP ribose transferases" :
2 publications dans cette catégorie
Affiliations :
Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, California 90089, United States.
Publications dans "ADP ribose transferases" :
2 publications dans cette catégorie
Affiliations :
Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, California 90089, United States.
Publications dans "ADP ribose transferases" :
2 publications dans cette catégorie
Affiliations :
Department of Biosciences and Nutrition, Karolinska Institute, Huddinge, Sweden.
Publications dans "ADP ribose transferases" :
2 publications dans cette catégorie
Affiliations :
Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA.
Publications dans "ADP ribose transferases" :
Diquafosol enhances fluid transfer and mucin secretion on ocular surface, which has been suggested as an effective treatment for dry eye disease (DED). The aim of the systematic review and meta-analys...
Relevant randomized controlled trials were obtained via search of electronic including PubMed, Embase, Cochrane Library, and Web of Science. A random-effects model was used to pool the results after i...
A total of nine RCTs involving 1295 patients with DED were included in the meta-analysis. Compared to treatment with 0.1% HA, topical treatment with 3% diquafosol significantly improved the Ocular Sur...
Topical treatment with 3% diquafosol may be more effective than 0.1% HA for patients with DED. However, the long-term efficacy and tolerability of diquafosol still need to be determined....
Narrowband ultraviolet B (NB-UVB) phototherapy is commonly prescribed for patients with moderate-to-severe atopic eczema (AE). The efficacy of NB-UVB, however, has not yet properly been established, a...
A pragmatic, multicenter, PROBE trial will be performed with 1:1 randomization of 316 adult patients with moderate-to-severe AE who have inadequate disease control with topical therapy and who are eli...
The UPDATE trial aims to provide high-quality evidence regarding the (cost-)effectiveness and safety of NB-UVB phototherapy in moderate-to-severe AE patients. Challenges that are addressed in the prot...
ClinicalTrials.gov NCT05704205. Registered on December 8, 2022....
Topical drugs are often used as first-line treatment for dermatological conditions. A within-person design may then be well adapted: it consists of randomizing lesions/body sites rather than patients,...
The aim of this review was to provide a methodological overview of within-person randomized trials (WP-RCTs) in dermatology....
We searched for eligible trials published between 2017 and 2021 in MEDLINE, Embase, and Central in dermatology journals and the 6 highest-impact-factor general medical journals. Two authors selected p...
From 1,034 articles identified, we included 54 WP-RCTs, mainly for acne vulgaris, psoriasis, actinic keratosis, and atopic dermatitis. In most of the trials, patients had only 2 lesions/body sites. In...
Our systematic review highlights that despite the publication of the CONSORT checklist extension for WP-RCTs in 2017, this design is rarely used, and when it is, there are methodological and reporting...
We aim to evaluate the clinical efficacy and safety of using laser and light combined with topical minoxidil for alopecia areata. We searched PubMed, Embase, Web of Science, the Cochrane Library, Chin...
Vulvar lichen sclerosus (LS) is a chronic debilitating inflammatory skin disease. Today, the gold standard is a life-long topical steroid treatment. Alternative options are highly desired. We present ...
We recruited 66 patients, 44 in the laser arm and 22 in the steroid arm. Patients with a physician-administered clinical LS score ≥ 4 were included. Participants received either four laser treatments ...
The findings of this trial have the potential to offer a novel treatment option for LS. The standardized Nd:YAG/Er:YAG laser settings and the treatment regime are presented in this paper....
NCT03926299....
Alopecia areata (AA) is a common autoimmune skin disease. Our study aimed to systematically evaluate the efficacy and safety of compound glycyrrhizin (CG) combined with topical minoxidil therapy in tr...
We searched the PubMed, EMBASE, Cochrane Library, Web of Science, CNKI, Wanfang, and VIP databases. Randomized controlled trials (RCTs) on CG combined with topical minoxidil therapy compared with topi...
11 RCTs and 1189 patients were included. Compared with topical minoxidil therapy alone, CG combined with topical minoxidil therapy was more effective at improving the clinical efficacy (RR = 1.36, 95%...
The current evidence indicates that CG combined with topical minoxidil therapy is effective and safe for AA. However, owing to the suboptimal quality of the included studies, more high-quality and lar...
The purpose was to identify and summarize the existing evidence on the efficacy and safety of the topical application of olive oil for preventing pressure ulcers (PUs). We included only randomized con...
To investigate the clinical efficacy and safety of topical difamilast in mild-to-moderate atopic dermatitis (AD)....
Only randomized controlled trials (RCTs) that compared topical difamilast with vehicle treatment for patients with AD were included. PubMed, Web of Science, Ovid Medline, Cochrane Library, ClinicalTri...
Five studies enrolling a total of 1009 patients with mild-to-moderate AD were identified. Compared with the topical vehicle, topical difamilast was associated with a significantly higher success rate ...
This meta-analysis suggests that topical difamilast is an effective and safe treatment for mild-to-moderate AD....
Melasma is a chronic relapsing skin condition. Laser therapy is a new advancement in treatment. Whether the topical application of tranexamic acid (TXA) increases the efficacy of laser therapy in mela...
Randomized controlled trials are used to estimate the causal effect of a treatment on a health outcome of interest in a patient population. Often the specified treatment in a randomized controlled tri...
We use causal reasoning to explain why randomized controlled trials of biomarker targets can arrive at conflicting or misleading conclusions. We describe four key threats to the validity of trials of ...
We illustrate these findings using evidence from 15 randomized controlled trials of blood pressure targets for management of hypertension. Randomized trials of blood pressure targets exhibit substanti...
Researchers should critically assess meta-analyses of trials of targets for variation in the types, distributions, and off-target effects of therapies studied. Trial investigators should release detai...